Poolbeg Pharma PLC Secures Major POLB 001 Patent in USA

Poolbeg Pharma, a biopharmaceutical company with a focus on developing and commercializing innovative medicines for diseases with significant unmet medical needs, has announced the successful grant of a patent by the US Patent Office for its Immunomodulator II application. This patent, which covers a class of drugs including POLB 001, is aimed at treating and preventing hypercytokinaemia, commonly known as a cytokine storm, which can occur following an immune response. The patent's scope includes cytokine storms induced by any disease indication, thereby reinforcing Poolbeg Pharma's intellectual property portfolio and enhancing the appeal of POLB 001 to potential pharmaceutical partners.

Poolbeg Pharma is engaged in building a comprehensive global intellectual property portfolio. This includes patents for p38 MAP kinase inhibitors used in treating severe influenza, and for POLB 001 in addressing hypercytokinaemia. The company has also filed further patent applications to broaden the coverage of POLB 001 and other p38 MAP kinase inhibitors, especially for treating cytokine release syndrome (CRS) that can follow cancer immunotherapy.

Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, emphasized the importance of the US patent grant, stating it highlights the ongoing progress in the development and fortification of the patent portfolio for POLB 001 across various disease indications. This advancement not only increases the value of POLB 001 but also makes it more attractive to potential partners in the pharmaceutical industry.

Skillington expressed confidence in POLB 001's potential to address unmet medical needs, particularly in cancer immunotherapy-induced CRS and severe influenza. The company estimates a significant market opportunity, exceeding US$10 billion, for cancer immunotherapy-induced CRS. Poolbeg believes that POLB 001 can significantly impact patient health and healthcare systems, thereby generating substantial value for shareholders.

Poolbeg Pharma is dedicated to the development and commercialization of drugs targeting diseases with high unmet medical needs, with a growing focus on rare and orphan diseases. The company aims to develop its clinical assets and commercialize approved drugs to support its growth and expand its pipeline of innovative products. Poolbeg's clinical programs target large markets, including cancer immunotherapy-induced CRS, infectious diseases, and metabolic conditions such as obesity, through the development of an oral GLP-1R agonist.

The company employs a cost-effective development strategy to produce high-quality human data, supporting further development and partnerships. Its AI-led infectious disease programs leverage data from human challenge trials to identify relevant drug targets and treatments, facilitating faster development and increasing commercial appeal.

Poolbeg Pharma's leadership team comprises experienced professionals with a history of creating significant shareholder value. The team has recently been reinforced by the addition of former members from the Amryt Pharma leadership team, with the goal of replicating Amryt's success and generating near-term revenues.

Overall, Poolbeg Pharma is poised to make significant advancements in the biopharmaceutical field, driven by its robust intellectual property portfolio, strategic development programs, and experienced leadership, all aimed at addressing critical medical needs and creating value for stakeholders.